He reported reduced viral load in the manuscript May 5, which for me was a fascinating observation. The receptor for Sars-Cov2 is AE2 allowing viral entry and subsequent viral replication. Interestingly reduction of the viral load must be mediated by restoration of the CD4/CD8 t cell ratio, which would suggested cell mediated viral kill is naturally achieved. Much different from the anti virals with no side effects! In light of the redimisvir study the exclusion of renal failure and increase in liver enzyme will leave the healthier patients in the study group, not mentioned by the media and subsequent retraction by Lancet. The publication will be a blockbuster.
On an different topic Tony in a very short phrase regarding redemsivir, "Not a home run, perhaps in combination with an HIV drug could be the answer". As he is a specialist in HIV, I think we all know what he was referring to! That was several months ago.